文献速递浆细胞疾病

冒烟型多发性骨髓瘤的风险分层:游离轻链与基于组的轨迹模型的预测价值

Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
PubMed 文献 · Blood Adv · 2018-01-01

研究纳入273例冒烟型多发性骨髓瘤患者,中位随访74个月,评估血清游离轻链比值≥100、骨髓浆细胞≥60%及基于组的轨迹模型识别的演变生物标志物的预测价值。结果确认游离轻链比值≥100和骨髓浆细胞≥60%与较高的2年进展风险相关,而血红蛋白、M蛋白和游离轻链差的演变轨迹可帮助识别超高危组。

要点

  • 游离轻链比值≥100者中位进展时间40个月,2年进展风险44%,但44%未进展。
  • 骨髓浆细胞≥60%者中位进展时间31个月,2年进展风险41%。
  • 免疫麻痹、血红蛋白演变、M蛋白演变和游离轻链差演变同时存在3个及以上变量时,中位进展时间仅13个月。

核心结论

  • 研究确认游离轻链比值≥100和骨髓浆细胞≥60%与较温和的2年进展风险相关,并提示血红蛋白演变、M蛋白演变和游离轻链差演变可能有助于识别超高危冒烟型多发性骨髓瘤组。

研究设计与样本

  • 研究纳入273例冒烟型多发性骨髓瘤患者,中位随访74个月,评估游离轻链比值≥100、骨髓浆细胞≥60%及基于组的轨迹模型识别的演变生物标志物的预测作用。

主要发现

  • 游离轻链比值≥100者中位进展时间40个月,2年进展风险44%,但44%的游离轻链比值≥100者在随访期间未进展。
  • 核心活检显示骨髓浆细胞≥60%者中位进展时间31个月,2年进展风险41%。
  • 基于组的轨迹模型在诊断后1年内识别出高危轨迹:血红蛋白演变(血红蛋白下降1.57 g/dL)、M蛋白演变(M蛋白增加64%)和游离轻链差演变(dFLC增加169%),均与中位进展时间缩短和2年进展风险升高相关。
  • 在所有 examined 变量中,免疫麻痹、血红蛋白演变、M蛋白演变和游离轻链差演变为超高危进展的显著预测因素,存在3个及以上变量时中位进展时间仅13个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the predictive role for serum free light chain ratio (FLCr) ≥100, bone marrow plasma cell (BMPC) ≥60%, and evolving biomarkers through group-based trajectory modeling (GBTM) as high-risk defining events in 273 smoldering multiple myeloma (SMM) patients with a median follow-up of 74 months. FLCr ≥100 was confirmed as a marker for high-risk progression with a median time to progression (TTP) of 40 months with a 44% risk of progression of disease (PD) at 2 years; however, 44% of FLCr ≥100 also did not progress during follow-up. For patients with BMPC ≥60% by core biopsy, the median TTP was 31 months with a 2-year PD of 41%. GBTM established high-risk trajectories for evolving hemoglobin (eHb; characterized as a 1.57 g/dL decrease in hemoglobin), evolving m-protein (eMP; 64% increase in m-protein), and evolving differences in FLC (edFLC; 169% increase in dFLC) within 1 year of diagnosis associated with a decreased median TTP and an increased 2 year rate of PD. Of all the variables examined, we identify a model where immunoparesis, eHb, eMP, and edFLC were significant predictors for ultra-high-risk progression with a median TTP of only 13 months with 3 or more variables present. Our results not only confirm a more modest 2 year PD associated with FLCr ≥100 and BMPC ≥60 but also suggest that eHb, eMP, and edFLC may help identify an ultra-high-risk SMM group.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018. PMID: 29945937. doi:10.1182/bloodadvances.2018016998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。